Intratumor morphologic and transcriptomic heterogeneity in
(V600E)BRAF-mutated colorectal cancer
consensus molecular subtypes
gene expression profiling
morphologic heterogeneity
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
12
05
2021
revised:
23
06
2021
accepted:
25
06
2021
pubmed:
17
7
2021
medline:
30
10
2021
entrez:
16
7
2021
Statut:
ppublish
Résumé
Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma. A series of 120 Thirty-one out of 120 (25.8%) Although the distribution of the immune infiltrate appears relatively conserved among heterogeneous areas of the same tumor, changes in gene expression profile and CMS occur in 50% of
Sections du résumé
BACKGROUND
Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma.
MATERIALS AND METHODS
A series of 120
RESULTS
Thirty-one out of 120 (25.8%)
CONCLUSIONS
Although the distribution of the immune infiltrate appears relatively conserved among heterogeneous areas of the same tumor, changes in gene expression profile and CMS occur in 50% of
Identifiants
pubmed: 34271310
pii: S2059-7029(21)00172-1
doi: 10.1016/j.esmoop.2021.100211
pmc: PMC8282957
pii:
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100211Subventions
Organisme : Cancer Research UK
ID : A18052
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22909
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure NV received honoraria from Merck Serono, Pfizer, Bayer, Eli-Lilly and Menarini Silicon Biosystems. FL had roles as consultant or advisor for Roche, Bayer, Amgen and Genentech. SL had roles as consultant or advisor for Amgen, Bayer, Merck Serono and Lilly; she received research funding from Amgen and Merck Serono and is part of speakers' bureau of Lilly and BMS. VZ received honoraria and had roles as consultant or advisor for Bristol-Myers Squibb, Bayer, Roche, Pfizer, Janssen, Novartis, Astellas and Servier; he had roles as consultant or advisor for Celgene and Merck. MF received research funding from Astellas Pharma, Macrophage Pharma and QED Therapeutics and had roles as consultant or advisor for Astellas Pharma, Roche, GSK-Tesaro and Diaceutics. All other authors have declared no conflicts of interest.